Ionis Pharmaceuticals Inc (IONS) SVP Sells $35,475.00 in Stock

Ionis Pharmaceuticals Inc (NASDAQ:IONS) SVP Patrick R. O’neil sold 645 shares of the firm’s stock in a transaction on Thursday, January 25th. The shares were sold at an average price of $55.00, for a total transaction of $35,475.00. Following the completion of the transaction, the senior vice president now owns 15,097 shares in the company, valued at $830,335. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Shares of Ionis Pharmaceuticals Inc (NASDAQ IONS) traded up $0.01 during trading on Monday, reaching $52.96. 1,727,389 shares of the company’s stock were exchanged, compared to its average volume of 1,071,957. The company has a current ratio of 6.25, a quick ratio of 6.21 and a debt-to-equity ratio of 1.50. Ionis Pharmaceuticals Inc has a 12-month low of $37.26 and a 12-month high of $65.51. The company has a market cap of $6,590.00, a P/E ratio of 378.29 and a beta of 2.86.

A number of institutional investors have recently modified their holdings of the business. The Manufacturers Life Insurance Company boosted its holdings in Ionis Pharmaceuticals by 9.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,744 shares of the company’s stock valued at $190,000 after purchasing an additional 311 shares during the period. Parametric Portfolio Associates LLC boosted its holdings in Ionis Pharmaceuticals by 0.4% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 100,250 shares of the company’s stock valued at $5,100,000 after purchasing an additional 387 shares during the period. Prudential Financial Inc. boosted its holdings in Ionis Pharmaceuticals by 4.9% in the 2nd quarter. Prudential Financial Inc. now owns 8,641 shares of the company’s stock valued at $440,000 after purchasing an additional 400 shares during the period. First Allied Advisory Services Inc. boosted its holdings in Ionis Pharmaceuticals by 9.9% in the 2nd quarter. First Allied Advisory Services Inc. now owns 5,463 shares of the company’s stock valued at $279,000 after purchasing an additional 494 shares during the period. Finally, Advisor Group Inc. boosted its holdings in Ionis Pharmaceuticals by 7.8% in the 2nd quarter. Advisor Group Inc. now owns 9,733 shares of the company’s stock valued at $475,000 after purchasing an additional 708 shares during the period. 91.43% of the stock is owned by hedge funds and other institutional investors.

A number of research firms recently issued reports on IONS. Needham & Company LLC reiterated a “buy” rating and issued a $64.00 target price on shares of Ionis Pharmaceuticals in a research note on Tuesday, October 17th. BMO Capital Markets reiterated an “outperform” rating and issued a $69.00 target price on shares of Ionis Pharmaceuticals in a research note on Monday, October 2nd. Zacks Investment Research lowered shares of Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, November 9th. Goldman Sachs Group reiterated a “sell” rating and issued a $30.00 target price on shares of Ionis Pharmaceuticals in a research note on Friday, October 6th. Finally, BidaskClub lowered shares of Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, December 22nd. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and six have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $50.76.

ILLEGAL ACTIVITY NOTICE: “Ionis Pharmaceuticals Inc (IONS) SVP Sells $35,475.00 in Stock” was published by American Banking News and is the property of of American Banking News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/29/ionis-pharmaceuticals-inc-ions-svp-sells-35475-00-in-stock.html.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Insider Buying and Selling by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply